Novo Banco's planned initial public offering would be beneficial for the Portuguese banking sector, Bank of Portugal Governor ...

Kepler Capital analyst David Evans maintained a Hold rating on Novo Nordisk (0QIU – Research Report) on February 5 and set a price target of ...

In a report released today, Elmar Kraus from DZ BANK AG maintained a Hold rating on Novo Nordisk (0QIU – Research Report). The company’s shares ...

Santander's Portuguese bank is not interested in buying Novo Banco, its CEO Pedro Castro Almeida said on Friday, as its ...

U.S. private equity firm Lone Star has told the Portuguese government that it is likely to sell a 25-30% stake in Novo Banco ...

The sources said Novo Banco was worth about 5 billion euros ($5.2 billion). Novo Banco, Portugal's fourth largest bank, was created in 2014 from the Portuguese government's bailout of collapsed ...

Welcome to the full-year 2024 Novo Nordisk earnings conference call. [Operator instructions] Please be advised that today's ...

LONDON/SAN FRANCISCO (Reuters) - Novo Nordisk (NYSE: NVO) is under pressure from investors for more information about its ...

The future of Portugal's Novo Banco is taking a clearer shape as US private equity firm Lone Star signals its intention to pursue an initial public offering (IPO) for a stake of up to 30% in the ...

Novo Nordisk - which manufactures Wegovy, Ozempic and Saxenda - misreported, under-reported or did not disclose funding it gave to pharmacy firms, obesity charities and other professional bodies ...

Novo Nordisk A/S investors got a much-needed boost from last week’s trial results for an experimental weight-loss shot. But there’s still a long way to go to claw back the declines of the past ...

(Reuters) -The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as death due to heart problems in diabetes patients with ...